- Home
- KTTA vs CHEK Comparison
KTTA vs CHEK Comparison
Compare KTTA & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- CHEK
- Stock Information
- Founded
- KTTA 2020
- CHEK 2004
- Country
- KTTA United States
- CHEK Israel
- Employees
- KTTA N/A
- CHEK 85
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- KTTA Health Care
- CHEK Health Care
- Exchange
- KTTA Nasdaq
- CHEK Nasdaq
- Market Cap
- KTTA 5.5M
- CHEK 4.8M
- IPO Year
- KTTA 2021
- CHEK 2015
- Fundamental
- Price
- KTTA $0.68
- CHEK $0.79
- Analyst Decision
- KTTA
- CHEK
- Analyst Count
- KTTA 0
- CHEK 0
- Target Price
- KTTA N/A
- CHEK N/A
- AVG Volume (30 Days)
- KTTA 142.8K
- CHEK 37.4K
- Earning Date
- KTTA 08-12-2025
- CHEK 08-14-2025
- Dividend Yield
- KTTA N/A
- CHEK N/A
- EPS Growth
- KTTA N/A
- CHEK N/A
- EPS
- KTTA N/A
- CHEK N/A
- Revenue
- KTTA N/A
- CHEK N/A
- Revenue This Year
- KTTA N/A
- CHEK N/A
- Revenue Next Year
- KTTA N/A
- CHEK N/A
- P/E Ratio
- KTTA N/A
- CHEK N/A
- Revenue Growth
- KTTA N/A
- CHEK N/A
- 52 Week Low
- KTTA $0.67
- CHEK $0.56
- 52 Week High
- KTTA $7.50
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- KTTA 32.67
- CHEK 47.47
- Support Level
- KTTA $0.67
- CHEK $0.75
- Resistance Level
- KTTA $0.77
- CHEK $0.83
- Average True Range (ATR)
- KTTA 0.04
- CHEK 0.04
- MACD
- KTTA 0.01
- CHEK 0.01
- Stochastic Oscillator
- KTTA 14.02
- CHEK 39.86
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.